SUMMARY OF PRODUCT CHARACTERISTICS
1. **NAME OF THE MEDICINAL PRODUCT**

   Duovir*

2. **QUALITATIVE AND QUANTITATIVE COMPOSITION**

   Each film-coated tablet contains 150 mg lamivudine and 300 mg zidovudine.

   For a full list of excipients see section 6.1.

3. **PHARMACEUTICAL FORM**

   Film-coated tablet

   Duovir tablets are white coloured, film coated, oblong, biconvex tablets with ‘DVR’ debossed on one side and plain on the other.

4. **CLINICAL PARTICULARS**

   4.1 **Therapeutic indications**

   Duovir is indicated in combination with another antiretroviral agent for the treatment of human immunodeficiency virus (HIV) infection in adults, adolescents and children weighing at least 25 kg.

   Consideration should be given to official treatment guidelines for HIV-1 infection (e.g. those of the WHO).

   4.2 **Posology and method of administration**

   Oral use.

   Therapy should be prescribed by a physician experienced in the management of HIV infection.

   **Patients weighing at least 25 kg**

   One tablet twice daily.

   Tablets may be taken with food or between meals, swallowed with some water or another drink.

   If the tablets cannot be swallowed whole, they may be crushed and combined with a small amount of semi-solid food or drink, and the whole dose taken immediately.

   **Patients weighing less than 25 kg**

   For these patients other formulations enabling administration of lower amounts of lamivudine and zidovudine are available (e.g. divisible tablets, tablets containing less active substances or liquid formulations).

   **Elderly**

   Special care is advised in the elderly because of age-associated changes such as decrease in renal function and alteration of haematological parameters.

   **Dose adjustments**

   For situations where discontinuation of therapy with one of the active substances of Duovir, or dose reduction is necessary, separate preparations of lamivudine and zidovudine are available as tablets and oral solutions.

   **Renal impairment**

---------------------------------------------------------------------------

* Trade names are not prequalified by WHO. This is under local drug regulatory authority’s responsibility.

Throughout this WHOPAR the proprietary name is given as an example only.
Since dose adjustment may be necessary in patients with renal impairment (creatinine clearance \(\leq 50\, \text{ml/minute}\)), it is recommended that separate preparations of lamivudine and zidovudine be administered (see section 4.4).

**Hepatic impairment**

No dose adjustment is necessary for mild to moderate hepatic impairment.

In patients with severe hepatic impairment, dose adjustment for zidovudine may be necessary. Therefore, it is recommended that separate preparations of lamivudine and zidovudine be administered in these patients (see section 4.4).

**Haematological adverse reactions**

Since substitution or dose reduction of zidovudine should be considered in patients whose haemoglobin concentrations or neutrophil counts fall to clinically significant levels, it is recommended that separate preparations of lamivudine and (if appropriate) zidovudine be administered (see section 4.4).

**Missed dose**

If a dose is missed it should be taken as soon as it is noted. If the next dose is due in less than 6 hours, the forgotten dose should be skipped and the next regular dose should be taken when it is due. No double dose should be taken to make up for missed doses.

### 4.3 Contraindications

Duovir is contraindicated in patients with:

- Hypersensitivity to lamivudine, zidovudine or to any excipient in the formulation,
- Abnormally low neutrophil count (< 0.75 x 10^9/litre) (see section 4.4),
- Abnormally low haemoglobin (< 7.5 g/dl or 4.65 mmol/litre) (see section 4.4).

### 4.4 Special warnings and special precautions for use

Lamivudine and zidovudine should only be used with abacavir in the treatment of antiretroviral-naïve patients when a regimen based on a protease inhibitor (PI) or a non-nucleoside reverse transcriptase inhibitor (NNRTI) cannot be used.

Concomitant use of stavudine with zidovudine should be avoided (see section 4.5).

**Dose adjustment**

It is recommended that separate preparations of lamivudine and zidovudine be administered when any dosage adjustment is necessary (see section 4.2). In these cases the health care provider should refer to the individual prescribing information for each of the products.

**Opportunistic infections**

Patients receiving antiretroviral therapy may continue to develop opportunistic infections and other complications of HIV infection. Therefore, patients should remain under close clinical observation by physicians or health care providers experienced in the treatment of HIV infection.

**Transmission of HIV**

Patients should be advised that current antiretroviral therapy has not been proven to prevent the risk of transmission of HIV to others through sexual contact or contamination with blood. Appropriate precautions should continue to be taken to prevent transmission.

**Haematological adverse reactions**

Anaemia, neutropenia and leucopenia have been reported in patients receiving zidovudine-containing preparations, especially in patients with advanced HIV disease (poor bone-marrow reserve) or with vitamin B₁₂ deficiency, and usually after at least 4–6 weeks of therapy.
Therefore, monitoring of haematological parameters is recommended in patients receiving Duovir, e.g. as follows:

− In advanced HIV disease: at least every 2 weeks during the first 3 months of therapy, and monthly thereafter.
− In early (non-symptomatic) HIV disease, at a frequency depending on the overall condition of the patient: e.g. every 1–3 months.

Since substitution, dose reduction or interruption of zidovudine therapy may be necessary in patients whose haemoglobin concentration or neutrophil count fall to clinically significant levels, separate preparations of lamivudine and (if appropriate) zidovudine should be administered (refer to the Summary of Product Characteristics of zidovudine-only containing products).

**Pancreatitis**

Treatment with Duovir should be stopped immediately if clinical signs, symptoms or laboratory abnormalities suggestive of pancreatitis occur.

**Lactic acidosis**

Lactic acidosis is a rare but severe, potentially life-threatening complication associated with nucleoside reverse transcriptase inhibitors (NRTI) use. It may occur after a few to several months of treatment. Patients with hyperlactataemia may be asymptomatic, critically ill, or may have non-specific symptoms such as dyspnoea, fatigue, nausea, vomiting, diarrhoea and abdominal pain. Risk factors for NRTI-related lactic acidosis include female gender and obesity. Patients co-infected with hepatitis C and treated with interferon alfa and ribavirin may constitute a special risk. Patients at increased risk should be closely monitored clinically. Screening for hyperlactataemia in asymptomatic patients treated with NRTIs, however, is not recommended. Symptomatic patients usually have lactic acid levels > 5 mmol/litre and require discontinuation of all NRTIs, including zidovudine and lamivudine. Lactic acid level > 10 mmol/litre is usually a medical emergency.

**Mitochondrial dysfunction**

Nucleoside and nucleotide analogues have been demonstrated *in vitro* and *in vivo* to cause a variable degree of mitochondrial damage. There have been reports of mitochondrial dysfunction in HIV-negative infants exposed to nucleoside analogues *in utero* or postnatally. The main adverse events reported are haematological disorders (anaemia and neutropenia), metabolic disorders (hyperlactataemia, hyperlipasaemia). These events are often transitory. Some late-onset neurological disorders have been reported (hypertonia, convulsion, abnormal behaviour). Whether these neurological disorders are transient or permanent is currently unknown. Any child exposed *in utero* to nucleoside and nucleotide analogues, even HIV-negative children, should have clinical and laboratory follow-up and should be fully investigated for possible mitochondrial dysfunction in case of relevant signs or symptoms. These considerations, however, do not affect recommendations to use antiretroviral therapy in pregnant women to prevent vertical transmission of HIV.

**Lipodystrophy**

Combination antiretroviral therapy has been associated with the redistribution of body fat (lipodystrophy) in HIV patients. A higher risk of lipodystrophy has been associated with, for example, older age, longer duration of ART and related metabolic disturbances. Clinical examination should include evaluation for physical signs of fat redistribution. Measurement of fasting serum lipids and blood glucose as well as appropriate management of lipid disorders should be considered (see section 4.8).

**Immune Reactivation Syndrome**

In HIV-infected patients with severe immune deficiency, typically in the first few weeks or months of initiating combination antiretroviral therapy, an inflammatory reaction to asymptomatic or residual opportunistic pathogens (e.g. CMV retinitis, mycobacterial infections, *Pneumocystis jirovecii* (*Pneumocystis carinii*) pneumonia) may arise and cause serious clinical conditions or aggravation of symptoms. Treatment should be instituted when necessary.
Liver disease

Caution should be exercised when administering Duovir to any patient with chronic hepatitis B infection. Lamivudine is a potent inhibitor of hepatitis B virus (HBV) replication and discontinuation of lamivudine or virological failure after development of resistance to lamivudine by HBV may cause hepatic deterioration and a hepatitis flare. If Duovir is discontinued in a patient with HBV infection, the patient should be periodically monitored, both clinically and by assessment of liver function tests (ALT and bilirubin levels) and markers of HBV replication, for at least 4 months, and then as clinically indicated.

Patients with chronic hepatitis B or C who are treated with combination antiretroviral therapy, have an increased risk of severe and potentially fatal hepatic adverse events.

Patients with liver dysfunction have an increased risk of liver function abnormalities during combination antiretroviral therapy, and should be monitored according to standard practice. If liver disease worsens in such patients, interruption or discontinuation of therapy should be considered.

Osteonecrosis

Although the aetiology is considered to be multifactorial (including corticosteroid use, alcohol consumption, severe immunosuppression, higher body mass index), cases of osteonecrosis have been reported, particularly in patients with advanced HIV-disease or long-term exposure to combination antiretroviral therapy. Patients should be advised to seek medical advice if they develop joint aches and pain, joint stiffness or difficulty in movement.

4.5 Interaction with other medicinal products and other forms of interaction

As Duovir contains lamivudine and zidovudine, any interactions that have been identified with these agents individually may occur.

Whereas lamivudine undergoes limited metabolism and is almost completely eliminated via the kidneys, zidovudine is primarily eliminated by hepatic conjugation, to form an inactive glucuronide metabolite. The following list of interactions is not exhaustive, but is representative of the classes of medicinal products where caution should be exercised.

Lamivudine and zidovudine are not significantly metabolised by cytochrome P450 enzymes (such as CYP3A4, CYP2C9 or CYP2D6) and do not inhibit or induce this enzyme system. Therefore, there is little potential for interactions with antiretroviral protease inhibitors, non-nucleosides and other medicinal products metabolised by major P450 enzymes.

The following list of interactions is not exhaustive, but is representative of the classes of medicinal products where caution should be exercised.

<table>
<thead>
<tr>
<th>Drugs</th>
<th>Interaction</th>
<th>Recommendation concerning co-administration</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Geometric mean change (%) (&lt;Possible mechanism&gt;)</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Recommendation concerning co-administration</td>
<td></td>
</tr>
<tr>
<td><strong>Antiretrovirals</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Emtricitabine/Lamivudine</td>
<td>Overlapping resistance and lack of additive antiretroviral effects.</td>
<td>Emtricitabine should not be co-administered with Duovir</td>
</tr>
<tr>
<td>Stavudine/Zidovudine</td>
<td><em>In vitro</em> antagonism of anti-HIV activity between stavudine and zidovudine could result in decreased efficacy of both drugs.</td>
<td>Concomitant use of stavudine with Duovir not recommended.</td>
</tr>
<tr>
<td><strong>Anti-infectives</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Clarithromycin/Zidovudine</td>
<td>Zidovudine AUC ↓12%</td>
<td>Administration of Duovir and clarithromycin should be separated by at least 2 hours.</td>
</tr>
</tbody>
</table>

(500 mg twice daily/100 mg every 4 hours)
### Drugs

<table>
<thead>
<tr>
<th>Drugs</th>
<th>Interaction Geometric mean change (%) (Possible mechanism)</th>
<th>Recommendation concerning co-administration</th>
</tr>
</thead>
<tbody>
<tr>
<td>Lamivudine/Zidovudine (600 mg once daily/200 mg three times daily)</td>
<td>Lamivudine AUC ↓48% (UGT induction)</td>
<td>Insufficient data to recommend dosage adjustment.</td>
</tr>
<tr>
<td>Trimethoprim + sulfamethoxazole/Lamivudine (160 mg/800 mg once daily for 5 days/300 mg single dose)</td>
<td>Lamivudine: AUC ↑40% Trimethoprim: AUC ↔ Sulfamethoxazole: AUC ↔ (Organic cation transporter inhibition)</td>
<td>No dosage adjustment of Duovir necessary, unless patient has renal impairment (section 4.2). When concomitant administration with trimethoprim + sulfamethoxazole is warranted, patients should be monitored clinically. High doses of trimethoprim + sulfamethoxazole for treating <em>Pneumocystis jirovecii</em> (<em>Pneumocystis carinii</em>) pneumonia and toxoplasmosis have not been studied and should be avoided.</td>
</tr>
</tbody>
</table>

#### Antifungal

<table>
<thead>
<tr>
<th>Drugs</th>
<th>Interaction Geometric mean change (%) (Possible mechanism)</th>
<th>Recommendation concerning co-administration</th>
</tr>
</thead>
<tbody>
<tr>
<td>Fluconazole/Zidovudine (400 mg once daily/200 mg three times daily)</td>
<td>Zidovudine AUC ↑74% (UGT inhibition)</td>
<td>The clinical significance is not known. Monitor for signs of zidovudine toxicity (section 4.8).</td>
</tr>
</tbody>
</table>

#### Antimalarial

<table>
<thead>
<tr>
<th>Drugs</th>
<th>Interaction Geometric mean change (%) (Possible mechanism)</th>
<th>Recommendation concerning co-administration</th>
</tr>
</thead>
<tbody>
<tr>
<td>Atovaquone/Zidovudine (750 mg twice daily with food/200 mg three times daily)</td>
<td>Zidovudine AUC ↑33% Atovaquone AUC ↔</td>
<td>The clinical significance is not known.</td>
</tr>
</tbody>
</table>

#### Anticonvulsants

<table>
<thead>
<tr>
<th>Drugs</th>
<th>Interaction Geometric mean change (%) (Possible mechanism)</th>
<th>Recommendation concerning co-administration</th>
</tr>
</thead>
<tbody>
<tr>
<td>Phenobarbital/Zidovudine</td>
<td>Interaction not studied. Potential to slightly decrease zidovudine plasma concentrations through UGT induction.</td>
<td>Insufficient data to recommend dosage adjustment.</td>
</tr>
<tr>
<td>Phenytoin/Zidovudine</td>
<td>Phenytoin AUC ↑↓</td>
<td>Monitor phenytoin concentration.</td>
</tr>
<tr>
<td>Valproic acid/Zidovudine (250 mg or 500 mg three times daily/100 mg three times daily)</td>
<td>Zidovudine AUC ↑80% (UGT inhibition)</td>
<td>The clinical significance is not known. Monitor for signs of zidovudine toxicity (section 4.8).</td>
</tr>
</tbody>
</table>

#### Opioids

<table>
<thead>
<tr>
<th>Drugs</th>
<th>Interaction Geometric mean change (%) (Possible mechanism)</th>
<th>Recommendation concerning co-administration</th>
</tr>
</thead>
<tbody>
<tr>
<td>Methadone/Zidovudine (30–90 mg once daily/200 mg every 4 hours)</td>
<td>Zidovudine AUC ↑43% Methadone AUC ↔</td>
<td>The clinical significance is not known. Monitor for signs of zidovudine toxicity (section 4.8). Methadone dosage adjustment may be required only occasionally.</td>
</tr>
</tbody>
</table>

#### Uricosuric

<table>
<thead>
<tr>
<th>Drugs</th>
<th>Interaction Geometric mean change (%) (Possible mechanism)</th>
<th>Recommendation concerning co-administration</th>
</tr>
</thead>
<tbody>
<tr>
<td>Probenecid/Zidovudine(500 mg four times daily/2 mg/kg three times daily)</td>
<td>Zidovudine AUC ↑106% (UGT inhibition)</td>
<td>The clinical significance is not known. Monitor for signs of zidovudine toxicity (section 4.8).</td>
</tr>
</tbody>
</table>

### Abbreviations

<table>
<thead>
<tr>
<th>Abbreviation</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>↑ = Increase</td>
<td>↓ = decrease</td>
</tr>
<tr>
<td>↔ = no significant change</td>
<td>AUC = area under the concentration versus time curve</td>
</tr>
</tbody>
</table>
Exacerbation of anaemia due to ribavirin has been reported when zidovudine is part of the regimen used to treat HIV. Therefore, concomitant use of ribavirin with Duovir is not recommended (see section 4.4), particularly in patients with a history of zidovudine-induced anaemia. Concomitant treatment, especially acute therapy, with potentially nephrotoxic or myelosuppressive medicines (e.g. systemic pentamidine, dapsone, pyrimethamine, trimethoprim + sulfamethoxazole, amphotericin, flucytosine, ganciclovir, interferon, vincristine, vinblastine and doxorubicin) and zidovudine may increase the risk of adverse reactions. If concomitant therapy with Duovir and any of these medicines is necessary then extra care should be taken to monitor renal function and haematological parameters and, if required, the dose of one or more agents should be reduced.

4.6 Pregnancy and breastfeeding

Pregnancy
No increased risk of birth defects have been reported for lamivudine or for zidovudine (www.apregistry.com). However, risks to the fetus cannot be ruled out.

The use in pregnant women of zidovudine alone, with subsequent treatment of the newborn infants, has been shown to reduce the rate of maternal-fetal transmission of HIV-infection. However, no such data are available for lamivudine.

Breastfeeding
Both lamivudine and zidovudine are present in breast milk at concentrations similar to those in the serum. The most recent official treatment guidelines (e.g. those issued by WHO) should be consulted before advising mothers on breastfeeding.

4.7 Effects on ability to drive and use machines

No studies on the effects on the ability to drive and use machines have been performed. Nevertheless, the clinical status of the patient and the adverse reaction profile of Duovir should be borne in mind when considering the patient’s ability to drive or operate machinery.

4.8 Undesirable effects

As Duovir contains lamivudine and zidovudine, the type and severity of adverse reactions associated with each of the compounds may be expected. There is no evidence of added toxicity with concurrent administration of the two compounds.

The most frequently reported adverse reactions are headache and nausea. The most common serious adverse reactions include anaemia (which may require transfusions), neutropenia and leucopenia (see section 4.4).

Adverse events considered to be at least possibly related to treatment with zidovudine and lamivudine, are listed below by body system, organ class and absolute frequency. Frequencies are defined as very common (≥1/10), common (1/100–1/10), uncommon (1/1000–1/100), rare (1/10 000–1/1000) or very rare (≤1/10 000). In addition, adverse events identified during post-approval use of lamivudine, zidovudine, and lamivudine/zidovudine as a fixed-dose combination are listed. Since they are reported voluntarily from a population of unknown size, the frequency cannot be estimated (frequency category: ‘unknown’). These events have been included on the basis of their seriousness, number of reports, or potential causal connection to lamivudine, zidovudine, and lamivudine/zidovudine as fixed-dose combination.

Blood and lymphatic systems disorders

Common: Anaemia, neutropenia, leucopenia
Uncommon: Thrombocytopenia, pancytopenia
Rare: Pure red cell aplasia
Very rare: Aplastic anaemia
Metabolic and nutrition disorders

Rare: Lactic acidosis, anorexia
Unknown: changes in distribution of body fat, hypertriglyceridaemia, hypercholesterolaemia, insulin resistance, hyperglycaemia, hyperlactataemia (see section 4.4)

Psychiatric disorders

Rare: anxiety, depression

Nervous system disorders

Very common: Headache
Common: Dizziness, insomnia
Rare: Paraesthesia, somnolence, loss of mental acuity, convulsions

Cardiac disorders

Rare: Cardiomyopathy

Respiratory, thoracic and mediastinal disorders

Common: Cough, nasal symptoms
Uncommon: Dyspnœa

Gastrointestinal disorders

Very common: Nausea
Common: Vomiting, abdominal pain or cramps, diarrhoea
Uncommon: Flatulence
Rare: Pancreatitis, raised serum amylase, oral mucosa pigmentation, taste perversion, dyspepsia

Hepatobiliary disorders

Common: Elevated liver enzymes and bilirubin
Rare: Hepatitis, severe hepatomegaly with steatosis

Skin and subcutaneous tissue disorders

Common: Rash, hair loss
Uncommon: Pruritus
Rare: Nail and skin pigmentation, urticaria, sweating, angioedema

Musculoskeletal and connective tissue disorders

Common: Arthralgia, myalgia
Uncommon: Myopathy
Rare: Rhabdomyolysis
Unknown: osteonecrosis

Renal and urinary disorders

Rare: Urinary frequency

Reproductive system and breast disorders

Rare: Gynaecomastia

General disorders and administration site disorders:

Common: Malaise, fatigue, fever
Uncommon: Asthenia, generalised pain
Rare: Chest pain, influenza-like syndrome, chills
Unknown: Immune reconstitution syndrome (see section 4.4)

See also sections 4.4 and 4.5
4.9 Overdose

There is limited experience of overdosage with lamivudine/zidovudine. No specific signs and symptoms have been identified following acute overdose with zidovudine or lamivudine apart from those listed as undesirable effects. No fatalities occurred and the patients recovered. If overdose occurs patients should be monitored for toxicity (see section 4.8), and standard supportive treatment given as necessary. Since elimination of lamivudine and the glucuronide metabolite of zidovudine are enhanced by haemodialysis, continuous haemodialysis could be used in the treatment of overdosage (but this has not been studied).

5. PHARMACOLOGICAL PROPERTIES

5.1 Pharmacodynamic properties

Pharmacotherapeutic group: Antivirals for treatment of HIV infections, combinations, ATC Code J05AR01

Mechanism of action:

Lamivudine and zidovudine are nucleoside analogues that are active against HIV. Additionally, lamivudine has activity against hepatitis B virus (HBV). Both compounds are metabolised intracellularly to their active moieties, lamivudine 5'-triphosphate (TP) and zidovudine 5'-triphosphate respectively. Their main modes of action are as chain terminators of viral reverse transcription.

Lamivudine-TP and zidovudine-TP have selective inhibitory activity against HIV-1 and HIV-2 replication in vitro; lamivudine is also active against zidovudine-resistant clinical isolates of HIV. Lamivudine in combination with zidovudine exhibits synergistic anti-HIV activity against clinical isolates in cell culture.

Clinical efficacy:

In clinical trials, lamivudine in combination with zidovudine reduces HIV-1 viral load and increases CD4 cell count. Clinical end-point data indicate that lamivudine in combination with zidovudine, results in a significant reduction in the risk of disease progression and mortality. In a trial of zidovudine and lamivudine in combination with efavirenz, 68% of subjects achieved plasma HIV RNA < 50 copies/ml after 48 weeks, by intention-to-treat analysis. Lamivudine and zidovudine have been widely used as components of antiretroviral combination therapy with other antiretroviral agents of the same class (NRTIs) or different classes (protease inhibitors, non-nucleoside reverse transcriptase inhibitors).

Resistance:

In the great majority of cases when combination antiretroviral therapy comprising zidovudine and lamivudine fails virologically, the M184V mutation will be selected for at an early stage. M184V causes high-level resistance to lamivudine (> 300-fold reduced susceptibility). In vitro data suggest that continuation of lamivudine in antiretroviral regimen despite the development of M184V might provide residual antiretroviral activity (likely through impaired viral fitness). The clinical relevance of these findings is not established. Indeed, available clinical data are very limited and preclude any reliable conclusion in the field. Therefore, maintaining lamivudine therapy despite emergence of M184V mutation should be considered only when the activity of the best available NRTI backbone is significantly compromised.

On virological failure, resistance to zidovudine is developed along two separate, though not mutually exclusive, pathways. The first of these include M41L, L210W and T215F/Y. The second includes D67N, K70R and K219E/Q. Collectively these mutations are termed ‘thymidine analogue mutations’ (TAM). In viruses with M184V, two to three TAMs are generally required for phenotypically detectable and clinically significant zidovudine resistance. M41L, L210W, and T215Y have a greater effect on zidovudine susceptibility and cross-resistance to other NRTIs than the other TAMs. Other important mutations selected for by zidovudine include T69 insertion mutations and the Q151M complex, where this mutation appears in combination with mutations at positions 75, 77, and 116. Both of these patterns confer high-level resistance to zidovudine and all other presently available NRTIs.

The likelihood of a gradual accumulation of mutations conferring resistance to the entire class of NRTI, upon virological failure with combination therapy including zidovudine and lamivudine, underscores the importance of early detection of virological failure. Delayed detection of virological failure may severely limit the options for second-line therapy.
The combination of lamivudine and zidovudine has not been specifically investigated in HIV patients co-infected with HBV.

5.2 Pharmacokinetic properties

Absorption

Lamivudine and zidovudine are well absorbed from the gastrointestinal tract. The bioavailability of oral lamivudine in adults is normally between 80–85% and for zidovudine 60–70%.

Following single dose of Duovir in healthy volunteers, mean of lamivudine and zidovudine C\text{max} values were 1.7968 \mu g/mL and 2.0618 \mu g/mL, respectively and the corresponding values for AUC\text{∞} were 7.8499 \mu g\text{·}\text{hour}/\text{ml} and 2.4596 \mu g\text{·}\text{hour}/\text{ml}, respectively. The median lamivudine and zidovudine t\text{max} values were 1.10 hours and 0.50 hours respectively.

The extent of lamivudine and zidovudine absorption (AUC\text{T}) and estimates of half-life following administration of a respective fixed combination product (Combivir, GSK) with food were similar when compared to fasting subjects, although the rates of absorption (C\text{max}, t\text{max}) were slowed. Based on these data Duovir may be administered with food or between meals.

Administration of crushed tablets with a small amount of semi-solid food or liquid would not be expected to affect the pharmaceutical quality, and would therefore not be expected to alter the clinical effect. This conclusion is based on the physiochemical and pharmacokinetic data assuming that the patient ingests the full dose immediately after crushing the tablets.

Distribution

Intravenous studies with lamivudine and zidovudine showed that the mean apparent volume of distribution is 1.3 litre/kg and 1.6 litre/kg respectively.

Lamivudine exhibits linear pharmacokinetics over the therapeutic dose range and displays limited binding to the major plasma protein albumin (< 36% serum albumin \textit{in vitro}).

Zidovudine plasma protein binding is 34–38%. Drug interactions involving binding site displacement are not anticipated with Duovir.

Metabolism

Metabolism of lamivudine is a minor route of elimination. Lamivudine is predominantly cleared unchanged by renal excretion. The likelihood of metabolic drug interactions with lamivudine is low due to the small extent of hepatic metabolism (5–10%) and low plasma protein binding.

The 5'-glucuronide of zidovudine is the major metabolite in both plasma and urine, accounting for approximately 50–80% of the administered dose eliminated by renal excretion. 3'-amino-3'-deoxythymidine has been identified as a metabolite of zidovudine following intravenous dosing.

Elimination

The observed lamivudine half-life of elimination is 5 to 7 hours. The half-life of intracellular lamivudine triphosphate has been estimated to be approximately 22 hours. The mean systemic clearance of lamivudine is approximately 0.32 litre/hour/kg, with predominantly renal clearance (> 70%), including tubular secretion through the organic cationic transport system. Studies in patients with renal impairment show that lamivudine elimination is affected by renal dysfunction. Dose reduction is recommended for patients with creatinine clearance ≤ 50 ml/minute (see section 4.2).

In studies with intravenous zidovudine, the mean terminal plasma half-life was 1.1 hours and the mean systemic clearance was 1.6 litre/hour/kg. The half-life of intracellular zidovudine triphosphate has been estimated to be around 7 hours. Renal clearance of zidovudine is estimated to be 0.34 litre/hour/kg, indicating glomerular filtration and active tubular secretion by the kidneys. Zidovudine concentrations are increased in patients with advanced renal failure.
Special populations:

Pregnancy: The pharmacokinetics of lamivudine and zidovudine during pregnancy were similar to that of non-pregnant women.

Children: In general, lamivudine pharmacokinetics in paediatric patients are similar to adults. However, absolute bioavailability (approximately 55–65%) was reduced in paediatric patients aged below 12 years. In addition, systemic clearance values were greater in younger paediatric patients and decreased with age, approaching adult values at around 12 years of age.

In children over the age of 5–6 months, the pharmacokinetic profile of zidovudine is similar to that in adults. Zidovudine is well absorbed from the gut and at all dose levels studied in adults and children, the bioavailability was between 60–74%.

5.3 Preclinical safety data

Neither lamivudine nor zidovudine is mutagenic in bacterial tests, but like many nucleoside analogues they show activity in mammalian in vitro tests such as the mouse lymphoma assay. Lamivudine has not shown any genotoxic activity in in vivo studies at doses that produced plasma concentrations up to 40–50 times higher than clinical plasma levels. Zidovudine showed clastogenic effects in an oral repeated dose micronucleus test in mice.

A transplacental genotoxicity study in monkeys compared zidovudine alone with the combination of zidovudine and lamivudine at exposures equivalent to those in humans. That study demonstrated that fetuses exposed in utero to the combination sustained a higher level of nucleoside analogue-DNA incorporation into multiple fetal organs, and showed evidence of more telomere shortening than in those exposed to zidovudine alone. The clinical significance of these findings is unknown.

The carcinogenic potential of a combination of lamivudine and zidovudine has not been tested. In oral carcinogenicity studies in rats and mice, lamivudine did not show any carcinogenic potential. In oral carcinogenicity studies with zidovudine in mice and rats, late-appearing vaginal epithelial tumours were observed. A subsequent intravaginal carcinogenicity study confirmed the hypothesis that the vaginal tumours were the result of long-term local exposure of the rodent vaginal epithelium to high concentrations of unmetabolised zidovudine in urine. No other zidovudine-related tumours were observed in either sex of either species.

In addition, two transplacental carcinogenicity studies have been conducted in mice. In one study zidovudine was administered at maximum tolerated doses to pregnant mice from day 12 to 18 of gestation. One year post-natally, there was an increase in the incidence of tumours in the lung, liver and female reproductive tract of offspring exposed to the highest dose level (420 mg/kg term body weight).

In a second study, mice were administered zidovudine at doses up to 40 mg/kg for 24 months, with exposure beginning prenatally on gestation day 10. Treatment-related findings were limited to late-occurring vaginal epithelial tumours, which were seen with a similar incidence and time of onset as in the standard oral carcinogenicity study. The second study thus provided no evidence that zidovudine acts as a transplacental carcinogen.

In reproductive toxicity studies lamivudine has demonstrated evidence of increasing early embryonic deaths in the rabbit at relatively low systemic exposures, comparable to those achieved in man, but not in the rat even at very high systemic exposure. Zidovudine had a similar effect in both species, but only at very high systemic exposures. Lamivudine was not teratogenic in animal studies. At maternally toxic doses, zidovudine given to rats during organogenesis resulted in an increased incidence of malformations, but no evidence of fetal abnormalities was observed at lower doses.
6. PHARMACEUTICAL PARTICULARS

6.1 List of excipients

CORE
Colloidal silicon dioxide
Microcrystalline cellulose
Sodium starch glycollate
Magnesium stearate

COATING
Hydroxypropyl methyl cellulose
Talc
Titanium dioxide
Propylene glycol

6.2 Incompatibilities

Not applicable

6.3 Shelf life

36 months (Blister pack)
42 months (HDPE bottle pack)

6.4 Special precautions for storage

Do not store above 30°C

6.5 Nature and contents of container

PVC/PVDC/Al blister of 10 or 14 tablets

HDPE bottle pack (cylindrical, white, opaque, induction-sealed 85 ml HDPE bottles fitted with white 38mm HDPE continuous thread closures and containing 1gm silica gel desiccant) of 60 tablets.

HDPE bottle pack (cylindrical, white, opaque, induction-sealed 65 ml HDPE bottles fitted with white 45mm HDPE continuous thread closures and containing 1gm silica gel desiccant) of 60 tablets

6.6 Instructions for use and handling and disposal

No special requirements.

7. Supplier

Cipla Ltd.,
Mumbai Central,
Mumbai 400 008
India

8. WHO REFERENCE NUMBER (PREQUALIFICATION PROGRAMME)

HA060

9. DATE OF FIRST PREQUALIFICATION / RENEWAL OF THE PREQUALIFICATION

30 November 2004

10. DATE OF REVISION OF THE TEXT

February 2013
Section 6 updated: October 2018

References


Further references relevant to sections of the SPC include:

**Section 4.2**

**Section 4.4**
Arenas-Pinto A et al., Sex Transm. Infect. 2003; 79: 340
Carr A., Clin Infect Dis 2003; 36 (Suppl.2): 596

**Section 4.5**
Squires KE et al., AIDS 2000; 14; 1591
Van Leeuwen R et al. AIDS 1992; 6, 1471

**Section 4.6**
Alvarez D et al., J Viral Hepat 2006; 13: 63-9

**Section 4.8**
Shapiro RL. et al., J. Infect. Dis. 2005; 192: 720
Pluda JM et al., J. Infect. Dis. 1995; 171: 1438
J. Fellay J et al., Lancet 2001; 358: 1322
Eron JJ Jr. et al., AIDS 2000; 14: 1601
Johri S. et al., AIDS 2000; 14: 1286
Coghlanc ME et al., Clin. Infect. Dis. 2001; 33: 1914
Fellay J et al., Lancet 2001; 358: 1322
Boubaker K et al., Clin. Infect. Dis. 2001; 33: 1931
Van Leeuwen R et al., AIDS 2003; 17: 987
Fong IW, Lancet 1994; 344: 1702
Section 5.1

Clinical efficacy
Squires KE et al., AIDS 2000; 14: 1591
Eron JJ Jr. et al., AIDS 2000; 14: 1601
Staszewski S al., JAMA 2001; 285: 1155
Carr A et al, AIDS 2000; 14: 1171
Podzamecer D et al., Antivir. Ther, 2002; 7: 81
French M et al., HIV. Clin. Trials 2002; 3: 177
Shafer RW et al., N. Engl. J. Med. 2003; 349: 2304
Paediatric European Network for Treatment of AIDS. Lancet 2002; 359:733

Resistance
Castagna A et al, AIDS 2006; 20: 795
Sungkanuparph S, Clin Inf Dis. 2007; 44: 447

Section 5.2

Anderson PL, AIDS 2003; 17: 2159